Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented ...

• A reduction in the risk of death was observed in the LUX-Lung 7 trial for patients treated with afatinib versus gefitinib, without reaching significance
• Updated results reaffirm that afatinib significantly improved progression-free survival and time to treatment failure, as well as increased overall response rate compared to gefitinib without compromising overall health-related quality of life, safety and tolerability

(BUSINESS WIRE)-- Boehringer Ingelheim today announced results from the LUX-Lung 7 trial that directly compared the efficacy and safety of second-generation EGFR-directed therapy afatinib* (Giotrif^®) and first-generation gefitinib (Iressa^®), in the first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). The trial investigated overall survival (OS) as a primary endpoint and a reduction in the risk of death (14%) was observed for patients treated with afatinib versus gefitinib. ...

Source : http://me-newswire.net//news/18822/en...